<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Michael</forename><surname>Schmueck-Henneresse</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute for Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Nephrology and Internal Intensive Care</orgName>
								<orgName type="laboratory">Renal and Transplant Research Unit</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies</orgName>
								<orgName type="institution">Charite ´Univer-sity Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Molecular Virology and Microbiology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies</orgName>
								<orgName type="institution">Charite ´Univer-sity Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bilal</forename><surname>Omer</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Shum</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Graduate Program of Translational Biology and Molecular Medicine</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Haruko</forename><surname>Tashiro</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maksim</forename><surname>Mamonkin</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Natalia</forename><surname>Lapteva</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandhya</forename><surname>Sharma</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Graduate Program of Translational Biology and Molecular Medicine</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lisa</forename><surname>Rollins</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gianpietro</forename><surname>Dotti</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Petra</forename><surname>Reinke</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Nephrology and Internal Intensive Care</orgName>
								<orgName type="laboratory">Renal and Transplant Research Unit</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies</orgName>
								<orgName type="institution">Charite ´Univer-sity Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Molecular Virology and Microbiology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans-Dieter</forename><surname>Volk</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute for Medical Immunology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Nephrology and Internal Intensive Care</orgName>
								<orgName type="laboratory">Renal and Transplant Research Unit</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies</orgName>
								<orgName type="institution">Charite ´Univer-sity Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Molecular Virology and Microbiology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cliona</forename><forename type="middle">M</forename><surname>Rooney</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Nephrology and Internal Intensive Care</orgName>
								<orgName type="laboratory">Renal and Transplant Research Unit</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies</orgName>
								<orgName type="institution">Charite ´Univer-sity Medicine Berlin</orgName>
								<address>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Center for Cell and Gene Therapy</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Houston Methodist Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Texas Children&apos;s Hospital</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Molecular Virology and Microbiology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">The American Association of Immunologists, Inc</orgName>
								<address>
									<addrLine>Suite 650</addrLine>
									<postCode>1451, 20852</postCode>
									<settlement>Rockville Pike, Rockville</settlement>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Institute for Medical Immunology and Berlin-Brandenburg Center for Regenerative Therapies</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>D-13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells</title>
					</analytic>
					<monogr>
						<idno type="ISSN">0022-1767</idno>
					</monogr>
					<idno type="MD5">3005103A311364CEAF956C65E6EA7812</idno>
					<idno type="DOI">10.4049/jimmunol.1601494</idno>
					<note type="submission">Received for publication August 26, 2016. Accepted for publication May 3, 2017.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:21+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>0000-0002-1479-5305 (B.O.)</term>
					<term>0000-0002-9038-1710 (H.T.)</term>
					<term>0000-0001-9183-1894 (S.S.)</term>
					<term>0000-0003-3210-2864 (C.M.R.)</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The outcome of therapy with chimeric Ag receptor (CAR)-modified T cells is strongly influenced by the subset origin of the infused T cells.</s><s>However, because polyclonally activated T cells acquire a largely CD45RO + CCR7 2 effector memory phenotype after expansion, regardless of subset origin, it is impossible to know which subsets contribute to the final T cell product.</s><s>To determine the contribution of naive T cell, memory stem T cell, central memory T cell, effector memory T cell, and terminally differentiated effector T cell populations to the CD3 and CD28-activated CAR-modified T cells that we use for therapy, we followed the fate and function of individually sorted CAR-modified T cell subsets after activation with CD3 and CD28 Abs (CD3/28), transduction and culture alone, or after reconstitution into the relevant subset-depleted population.</s><s>We show that all subsets are sensitive to CAR transduction, and each developed a distinct T cell functional profile during culture.</s><s>Naive-derived T cells showed the greatest rate of proliferation but had more limited effector functions and reduced killing compared with memory-derived populations.</s><s>When cultured in the presence of memory T cells, naive-derived T cells show increased differentiation, reduced effector cytokine production, and a reduced reproliferative response to CAR stimulation.</s><s>CD3/28-activated T cells expanded in IL-7 and IL-15 produced greater expansion of memory stem T cells and central memory T cell-derived T cells compared with IL-2.</s><s>Our strategy provides a powerful tool to elucidate the characteristics of CAR-modified T cells, regardless of the protocol used for expansion, reveals the functional properties of each expanded T cell subset, and paves the way for a more detailed evaluation of the effects of manufacturing changes on the subset contribution to in vitro-expanded T cells.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A</head><p><s>doptive T cell immunotherapy with chimeric Ag receptor (CAR)-modified T cells targeting tumor Ags has been incorporated into cancer treatment with promising efficacy in distinct settings <ref type="bibr" target="#b0">(1)</ref><ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref>.</s><s>CARs are genetically engineered immunoreceptors comprising a single-chain variable fragment linked to cytosolic endodomains from costimulatory receptors and/or the TCRz chain <ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b5">(6)</ref><ref type="bibr" target="#b6">(7)</ref>.</s><s>The structure of the CAR, including the affinity of the single-chain variable fragment, the type of spacer and costimulatory endodomains, the design of the clinical protocol, and the disease targeted profoundly affect the fate and function of CAR-modified T cells, as does the manufacturing protocol that determines the character of the T cell product infused <ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref><ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref>.</s><s>Data regarding the best T cell subset from which to derive CAR-modified T cells for infusion are inconclusive and controversial, and most patients receive CD4 + and CD8 + T cells whose subset derivation is unknown <ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref>.</s><s>The ultimate objective of T cell therapy is to transfer a long-lived T cell population with the capacity to differentiate into potent tumor-specific effectors and to self renew <ref type="bibr" target="#b7">(8,</ref><ref type="bibr" target="#b21">22)</ref>.</s><s>Short-lived effector T cells (T EFFs ) possess potent effector function in vitro; however, they appear to be less attractive for adoptive immunotherapy because of their limited proliferation and engraftment in vivo <ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref>.</s><s>Memory T cells subsets have been shown to expand substantially in vivo and are long-lived, with their self-renewal capacity being inversely proportional to their differentiation state <ref type="bibr" target="#b26">(26)</ref>.</s><s>Recently, it has been reported that Ag-experienced memory T cell subsets directly promote the phenotypic and functional differentiation of naive T cells (T naives ), which, as a consequence, lost antitumor potential when transferred in vivo <ref type="bibr" target="#b27">(27)</ref>.</s></p><p><s>Expression of the lymph node-homing molecules CCR7 and the leukocyte common Ag (CD45) isoforms RA and RO distinguishes memory T cells from T naives and allows the dissection of the memory/effector T cell compartment into at least four main subsets <ref type="bibr" target="#b28">(28,</ref><ref type="bibr" target="#b29">29)</ref>: memory stem T cells (T SCMs ), central memory T cells (T CMs ), effector memory T cells (T EMs ), and terminally differentiated T EFFs (T EMRAs ) <ref type="bibr" target="#b21">(22,</ref><ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b29">29)</ref>.</s><s>T CMs coexpress CCR7 and CD45RO, having lost CD45RA during naive → memory transition <ref type="bibr" target="#b30">(30)</ref>.</s><s>Upon antigenic restimulation, T CMs lose CCR7 expression and differentiate into T EMs <ref type="bibr" target="#b30">(30,</ref><ref type="bibr" target="#b31">31)</ref> and finally into T EMRAs, which are considered to be terminally differentiated.</s><s>T EMRAs lack CCR7 and CD45RO and re-express CD45RA <ref type="bibr" target="#b32">(32)</ref>.</s><s>A fourth memory subset, T SCMs , resides phenotypically within the naive-like T cell compartment (CD45RO 2 CD45RA + CCR7 + ) and can be distinguished from T naives by their expression of CD95 (Fas) <ref type="bibr" target="#b21">(22,</ref><ref type="bibr" target="#b29">29)</ref>.</s><s>Each T cell subset has distinct engraftment capacities and function following adoptive transfer in preclinical trials <ref type="bibr" target="#b29">(29)</ref><ref type="bibr" target="#b30">(30)</ref><ref type="bibr" target="#b31">(31)</ref><ref type="bibr" target="#b33">33)</ref>.</s><s>In particular, T CMs are thought to have superior engraftment and persistence compared with more differentiated memory T cell subsets <ref type="bibr" target="#b21">(22,</ref><ref type="bibr" target="#b26">26,</ref><ref type="bibr" target="#b28">(28)</ref><ref type="bibr" target="#b29">(29)</ref><ref type="bibr" target="#b30">(30)</ref><ref type="bibr" target="#b31">(31)</ref><ref type="bibr" target="#b33">(33)</ref><ref type="bibr" target="#b34">(34)</ref><ref type="bibr" target="#b35">(35)</ref><ref type="bibr" target="#b36">(36)</ref><ref type="bibr" target="#b37">(37)</ref>.</s><s>The recently described T SCM subset may represent the earliest stage of memory T cell differentiation, and it may have the ability to transfer stem cell-like T cells for improved long-term efficacy <ref type="bibr" target="#b38">(38,</ref><ref type="bibr" target="#b39">39)</ref>.</s></p><p><s>To identify the characteristics and subset derivation of CARmodified T cells polyclonally expanded on CD3 and CD28 Abcoated plates, as used in our clinical studies <ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref>, we sorted each T cell subset and followed its fate and function after activation, CAR transduction, and culture alone and after reconstitution into the corresponding subset-depleted polyclonally activated bulk PBMCs.</s><s>In a proof-of-concept study, we demonstrate that each T cell subset is sensitive to CAR transduction, and each displays a specific functional profile.</s><s>T naive -derived populations showed the most rapid expansion and dominated the cultures by the end of the culture period, but they had reduced effector functions and killing compared with memory subsets.</s><s>Furthermore, T naive -derived cells cultured in the presence of memory T cells differentiate more than when cultured alone and show coincidentally reduced effector cytokine production and ability to proliferate in response to CAR stimulation.</s><s>T SCMs show the most rapid expansion of all subsets; however, because of their low frequency at the start of culture, they represented only a minor fraction at the end.</s><s>Finally, we found that, compared with IL-2, a combination of IL-7 and IL-15 increased the yield of T SCM -and T CM -derived T cells within the bulk cultures.</s><s>Irrespective of the protocol used for expansion, our comprehensive approach reveals the characteristics of CAR-modified T cells polyclonally expanded from PBMCs, demonstrates the functional properties of each expanded T cell subset, and underscores the importance of culture conditions to influence the desired T cell populations.</s><s>To this end, our strategy allows a meticulous assessment of the effects of manufacturing changes on the subset contribution to in vitroexpanded T cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell culture</head><p><s>All PBMC and T cell cultures and all assays were performed using complete media (45% RPMI 1640 [HyClone, Logan, UT], 45% Click's Medium [Irvine Scientific, CA]) supplemented with 5 mM L-glutamine (Invitrogen, Carlsbad, CA), penicillin (100 IU/ml), and streptomycin (HyClone), containing 10% FBS (HyClone), in humidified incubators at 37˚C and 5% CO 2 .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood samples</head><p><s>For all experiments, blood samples were collected with informed consent from healthy volunteers using protocols approved by the Baylor College of Medicine Institutional Review Board.</s><s>PBMCs were isolated from blood by Lymphoprep density gradient centrifugation (STEMCELL Technologies, Vancouver, BC, Canada).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>T cell isolation and sorting</head><p><s>PBMCs were enriched for CD3 + T cells with the Pan T Cell Isolation Kit II (Miltenyi Biotec), following the manufacturer's instructions.</s><s>Cells were labeled with fluorescent Abs to CD3, CD45RO, CD95, CCR7 (all purchased from BioLegend), and CD45RA (Beckman Coulter).</s><s>FACS was performed for T CMs (CCR7 + CD45RA 2 ), T EMs (CCR7 2 CD45RA 2 ), T EMRAs (CCR7 2 CD45RA + ), T SCMs (CD45RA + CCR7 + → CD95 + ), and T naives (CD45RA + CCR7 + → CD95 2 ) <ref type="bibr" target="#b21">(22,</ref><ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b40">40)</ref> on a BD FACSAria II SORP (BD Biosciences).</s><s>Postsorting analysis of purified subsets revealed .98%</s><s>purity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell lines</head><p><s>NIH 293T, JEKO, and HDLM-2 cell lines (American Type Culture Collection, Manassas, VA) were cultured in IMDM (BioWhittaker, Walkersville, MD) supplemented with 10% FCS (HyClone) and 5 mM L-glutamine (Thermo Fisher, Waltham, MA).</s><s>Second-generation GD2.</s><s>CAR (14g2a.CD28z CAR)-transduced T cells were directed to the disialoganglioside (GD2) to assess specific in vitro re-expansion and effector function.</s><s>Expanded second-generation CD19.CAR + (FMC63.CD28z CAR) and CD19.CAR-NGFR + (FMC63.CD28z-I-NGFR CAR) T cells were analyzed for their ability to produce cytokines in response to CAR Ag-expressing target cells, which constituted the JEKO (CD19 + ) and HDLM-2 (CD19 2 ) cell lines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Constructs</head><p><s>We used CAR constructs directed to the disialoganglioside, GD2, and the B cell marker CD19 that have been targeted in many clinical studies.</s><s>Second-generation GD2.CAR (14g2a.CD28-z) and the CD19.CAR (FMC63.CD28z) cloned into SFG vectors were described previously <ref type="bibr" target="#b41">(41)</ref><ref type="bibr" target="#b42">(42)</ref><ref type="bibr" target="#b43">(43)</ref>.</s><s>The CD19.CAR construct was used alone and/or cloned upstream of an internal ribosome entry site (IRES)-nerve growth factor receptor (NGFR) or IRES mOrange to facilitate selection and detection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Retroviral supernatant</head><p><s>Transient retroviral supernatants were produced by cotransfection of NIH 293T cells with the MoMLV gag/pol expression plasmid PeqPam3(-env), the RD114(-env) expression plasmid RDF, and SFG vectors at a ratio of 3:2:3, with a total of 10 mg of DNA.</s><s>The transfection was facilitated with GeneJuice reagent (Calbiochem).</s><s>The supernatant was harvested 2 and 3 d after transfection, filtered (using a 0.45-mm filter), snap-frozen, and stored at 280˚C in 5-ml aliquots.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell stimulation and expansion</head><p><s>PBMCs or FACS-sorted T cells were activated on CD3 (from the OKT3 hybridoma; ATCC CRL-8001) and CD28 (BD, Franklin Lakes, NJ) Abcoated plates at 500 ml of 1 mg/ml each in the presence of recombinant human (rh)IL-2 (50 IU/ml) or rhIL-7 and rhIL-15 (each at 10 ng/ml).</s><s>In some experiments, CD3/28 Ab-activated subsets were transduced on day 2 after activation and then reconstituted into CD3/28-activated T cell subsetdepleted PBMCs on day 3 of culture at their initial frequency or cultured separately.</s><s>The medium and cytokines were changed every 3 d during culture or when passaging the T cells for splitting during expansion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transduction</head><p><s>T cells or T cell subsets were transduced 2 d after activation: nontissuetreated 24-well plates were coated with 500 ml of 1 mg/ml retronectin (Takara Biochemicals, Shiga, Japan) overnight.</s><s>After removing the retronectin, 1.5-2 ml of retroviral supernatant was added per well and centrifuged</s></p><p><s>The Journal of Immunology at 2000 3 g for 1 h at 25˚C to allow vector adherence.</s><s>The supernatant was removed prior to the addition of CD3/28-activated peripheral blood-derived T cells or FACS-sorted T cell subsets.</s><s>Cells were incubated for 2 d on the virus-coated plate in the presence of 50 IU/ml rhIL-2 (Proleukin; Chiron, Emeryville, CA) or 10 ng/ml rhIL-7 and 10 ng/ml rhIL-15 (PeproTech) and then transferred to tissue culture-treated plates.</s><s>Where indicated, 1 d after transduction, each T cell subset was reconstituted at its initial frequency into the corresponding subset-depleted population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Flow cytometry, Abs, and intracellular staining</head><p><s>Following Ag specific stimulation, cytokine production (IFN-g, TNF-a, IL-2) was determined by intracellular fluorescence staining.</s><s>All Abs were purchased from BioLegend, unless indicated otherwise.</s><s>GD2 + JF cell lines (serving as stimulator cells for second-generation GD2.CAR T cells) and CD19 + JEKO cell lines (serving as stimulator cells for second-generation CD19.CAR T cells) were added to T cells at a 10:1 stimulator/responder ratio.</s><s>HDLM-2 cells lacking GD2 and CD19 were used as controls, and respective background responses have been subtracted from CAR-specific cytokine production.</s><s>For effector cytokine detection, cultured T cells were restimulated for 6 h in the presence of 1 mg/ml brefeldin A (Sigma-Aldrich).</s><s>After harvesting, phenotype staining was performed using mAbs for CD3 (OKT3), CD4 (SK3), and CD8 (RPA-T8).</s><s>To define memory subsets, T cells were extracellularly stained for CCR7 (G043H7), CD45RA (HI100), CD45RO (UCHL1), and CD95 (DX2).</s><s>In particular experiments, an anti-NGFR (C40-1457; BD) Ab was used to stain for NGFR expression on CD19.CAR-NGFR + T cells.</s><s>Transduction efficacies were assessed by staining for CAR expression on the T cell surface using Abs targeting GD2 (IA7) <ref type="bibr" target="#b44">(44)</ref> or CD19.CAR [goat anti-human IgG (H+L); Jackson Immuno-Research, West Grove, PA].</s><s>To exclude dead cells, live/dead-discrimination staining dye (Invitrogen) was added.</s><s>Subsequently, cells were permeabilized with Permeabilizing Solution 2 (BD Biosciences) and stained for IFN-g (4S.</s><s>B3), TNF-a (MAb11), and IL-2 (MQ1-17H12).</s><s>Cells were analyzed on a LSR II flow cytometer using FlowJo version 10 software (TreeStar).</s><s>Lymphocytes were gated based on the forward scatter (FSC) versus the side scatter profile and subsequently gated on FSC (height) versus FSC to exclude doublets.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of cytotoxic activity</head><p><s>A modified VITAL assay was used for cytotoxicity testing, as described previously <ref type="bibr" target="#b21">(22,</ref><ref type="bibr" target="#b45">45,</ref><ref type="bibr" target="#b46">46)</ref>.</s><s>Briefly, the JEKO cell line served as a CD19 + target cell for second-generation CD19.CAR T cells, whereas HDLM-2 cells that lack CD19 were used as control targets.</s><s>JEKO cells were labeled with 10 mM CFSE (Molecular Probes).</s><s>As controls, CD19 2 HDLM-2 cells were labeled with 5 mM dimethyldodecylamine oxide-succinimidyl ester (Invitrogen).</s><s>Cells were cocultured in duplicate for 16 h at T cell/target cell ratios of 1:1 and 10:1.</s><s>Labeled cells were analyzed as duplicates using an LSR II flow cytometer.</s><s>Samples without T cells, containing only target cells (CD19 + JEKO cell lines or CD19 2 HDLM-2 cells), served as internal controls.</s><s>Cells were gated using live/dead discrimination staining-dye negative cells (Invitrogen).</s><s>The mean percentage of survival of CD19 + JEKO target cells was calculated relative to CD19 2 HDLM-2 controls.</s><s>Percentage target cell lysis was calculated as follows: mean percentage survival of targets in cultures containing defined numbers of T EFFs in comparison with control cells without T cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis and calculations</head><p><s>Statistical analysis was performed with GraphPad Prism version 6.</s><s>Data were analyzed using repeated-measures one-way ANOVA, two-way ANOVA, or a paired t test, as indicated, after verifying Gaussian distribution with the Kolmogorov-Smirnov test.</s><s>The p values # 0.05 were considered significant: *p , 0.05, **p , 0.01, ***p , 0.001.</s><s>T cell subset fold expansion expresses T cell subset numbers (assessed by FACS) in relation to total cell numbers on the indicated days after initial stimulation and day 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparative proliferation of isolated T cell subsets cultured alone</head><p><s>To analyze the characteristics of each T cell subset transduced with a GD2.CAR, we compared their proliferation and phenotype following CD3/28 Ab activation (in the presence of IL-7 and IL-15) and cytokine production following stimulation via the CAR using the CAR Ag (disialoganglioside: GD2).</s><s>First, CD3 + T cells were enriched from PBMCs by magnetic bead sorting and T CMs (CCR7 + CD45RA 2 ), T EMs (CCR7 2 CD45RA 2 ), T EMRAs (CCR7 2 CD45RA + ), T SCMs (CD45RA + CCR7 + → CD95 + ), and T naives (CD45RA + CCR7 + → CD95 2 ) were isolated by polychromatic FACS (Fig. <ref type="figure" target="#fig_0">1A</ref>).</s><s>The average frequency of each T cell subset from presorted CD3 + T cells was 21.5 6 6.2%, 17.8 6 8.8%, 9.8 6 5.5%, 0.9 6 0.2%, and 50.5 6 9.2%, respectively (Fig. <ref type="figure" target="#fig_0">1B</ref>).</s><s>To determine whether all T cell subsets isolated from PBMCs were sensitive to retroviral transduction, we transduced each subset with a second-generation CAR (14g2a.CD28-z) targeting GD2 (41) on day 2 after stimulation.</s></p><p><s>As presented in Fig. <ref type="figure" target="#fig_0">1C</ref>, GD2.CAR could be expressed in all T cell subsets, with median transduction efficacies of 60.2 6 10.2%, 60.1 6 7.2%, 66.6 6 7.9%, 61.2 6 7.1%, and 64.6 6 6.1% in CD4 + PBMC-derived T cells (T PBMCs ), T CMs , T EMs , T EMRAs , and T naives , respectively, and 65.6 6 20.7%, 70.8 6 15.4%, 75.3 6 12.3%, 61.7 6 16.8%, 66.6 6 19.2%, and 82.7 6 7.9% in CD8 + T PBMCs , T CMs , T EMs , T EMRAs , T SCMs , and T naives , respectively (summarized in Fig. <ref type="figure" target="#fig_1">2A</ref>).</s><s>We observed a trend toward higher transduction efficacies in CD8 + T cells compared with CD4 + T cells (70.4 and 62.5%, respectively) (Fig. <ref type="figure" target="#fig_1">2A</ref>).</s><s>As shown in Fig. <ref type="figure" target="#fig_1">2B</ref>, we detected a preferential expansion of CD8 + T cells compared with CD4 + T cells within T PBMC , T CM , T EM , T EMRA , and T SCM , but not T naive , populations.</s><s>As reported previously for T SCM -derived cells <ref type="bibr" target="#b21">(22)</ref>, we observed almost exclusive proliferation of CD8 + T SCMs , whereas CD4 + T SCM expansion could not be detected.</s><s>However, all other expanded T cell subsets showed a balanced CD4 + /CD8 + ratio (Fig. <ref type="figure" target="#fig_1">2A, 2B</ref>).</s><s>When cultured individually, all T cell subsets proliferated in response to CD3/28 stimulation, confirming their viability after separation, and all transduced T cell subsets showed rapid expansion, with the highest expansion at day 14 from T SCM -derived cells (311 6 63fold), followed by T naive -derived cells (210 6 24-fold) and T CMderived cells (150 6 65-fold) and lower expansion of T EM -derived cells (88 6 31-fold) and T EMRA -derived cells (61 6 22-fold) (Fig. <ref type="figure" target="#fig_1">2C</ref>).</s><s>All transduced subsets differentiated during culture, so that by day 14, CCR7 2 CD45RO + T EMs predominated in T EMRAand T EM -derived subsets, whereas a substantial proportion of CCR7 + CD45RO + T CMs was present in T CM -, T naive -and T SCMderived cultures (Fig. <ref type="figure" target="#fig_1">2D</ref>), demonstrating that T naives develop a memorylike phenotype in response to CD3/28 stimulation in vitro.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytokine production and proliferation of T cell subsets in response to CAR stimulation</head><p><s>To examine CAR-specific effector functions, we stimulated each transduced subset on day 14 with the GD2 + JF neuroblastoma cell line and a GD2 2 Hodgkin lymphoma cell line (HDLM2) and measured IFN-g cytokine expression in intracellular cytokine assays (Fig. <ref type="figure" target="#fig_1">2E</ref>).</s><s>GD2-specific IFN-g production from CD4 + and CD8 + T CM -, T PBMC -, and T SCM -derived cells was greater than from T naive -, T EMRA -, and T EM -derived cells.</s><s>No IFN-g was produced by nontransduced T cells in response to JF cells (data not shown).</s><s>To compare T cell subset proliferation in response to CAR stimulation, each transduced subset was stimulated with plate-bound GD2 (used to avoid tumor-derived activating or inhibitory signals) in the absence of exogenous cytokines on day 14 of culture.</s><s>Intriguingly, T EMRA -and T naive -derived cells failed to proliferate, whereas T SCM -, T CM -, and T EM -derived cells showed robust re-expansion in response to CAR Ag over 7 d of culture (Fig. <ref type="figure" target="#fig_1">2F</ref>).</s><s>However, T naive -derived cells did proliferate (18-fold expansion) when IL-7 and IL-15 were added to the re-expansion culture (data not shown), indicating greater dependence on exogenous cytokines than memory-derived T cells.</s></p><p><s>In summary, all tested T cell subsets were susceptible to CAR transduction and expanded when activated via the TCR, with by guest on May 17, 2022 http://www.jimmunol.org/</s><s>Downloaded from greatest fold expansion by T SCM -derived .</s><s>T naive -derived .</s><s>T CMderived .</s><s>T EM -derived .</s><s>T EMRA -derived cells.</s><s>Although lower in T EM -and T EMRA -derived cells, all subsets produced IFN-g following CAR stimulation and acquired a memory T cell phenotypic profile.</s><s>T SCM -, T CM -, and T EM -derived cells showed a greater capacity to expand in response to CAR stimulation than did T EMRAand T naive -derived cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Naive-derived T cells expand preferentially within polyclonally activated PBMCs but show reduced effector cytokine production and killing</head><p><s>To evaluate the characteristics of each T cell subset when reconstituted into the bulk subset-depleted PBMC population, each T cell subset was purified from PBMCs by FACS (Fig. <ref type="figure" target="#fig_2">3A, 3B</ref>), activated with CD3 and CD28 Abs, and transduced with a retroviral vector encoding a second-generation CD19.CD28z CAR and a truncated NGFR (CD19.CAR-NGFR), separated by an IRES to allow flow cytometric detection following expansion.</s><s>In parallel, each subset-depleted PBMC population was activated with CD3/28 Abs and transduced with the same second-generation CD19.CAR, but without NGFR (Fig. <ref type="figure" target="#fig_2">3C, 3D</ref>).</s><s>One day after transduction, each T cell subset was reconstituted at its initial frequency into the corresponding subset-depleted population.</s><s>This design allowed us to distinguish the depleted bulk-transduced PBMCs from the reconstituted transduced T cell subset by flow cytometric detection of NGFR (Fig. <ref type="figure" target="#fig_2">3D</ref>).</s><s>All T cell subsets were sorted to .98% purity (Fig. <ref type="figure" target="#fig_2">3B, 3C</ref>) and transduced with frequencies .</s><s>80% (Fig. <ref type="figure" target="#fig_2">3E</ref>).</s><s>CD19.CAR transduction did not affect the survival or expansion of any T cell subset compared with nontransduced subsets cultured alone in parallel (data not shown).</s></p><p><s>Differences in the rate of proliferation of each transduced subset, cultured alone or within the transduced bulk population, could not be detected (Fig. <ref type="figure" target="#fig_3">4A</ref>).</s><s>However, the rate of expansion of T cell subsets within the bulk culture was much greater for T naive -derived cells (CD3 + 234 6 36-fold expansion) and T SCM -derived cells (CD3 + 621 6 189-fold expansion) than for T EMRA -and T EM -derived cells (CD3 + 44 6 6-fold and 54 6 9-fold expansion), whereas T CM -derived cells showed an intermediate rate of expansion (CD3 + 204 6 48-fold expansion) (Fig. <ref type="figure" target="#fig_3">4A</ref>).</s><s>By day 14, T naivederived cells dominated the cultures (76 6 19% of CD3 + T cells), with T CM -derived cells accounting for 30 6 12% of CD3 + T cells (Fig. <ref type="figure" target="#fig_3">4B, 4C</ref>).</s><s>CD4 + and CD8 + T EMRA -and T EMderived cells could barely be detected because of the other more rapidly expanding subsets (Fig. <ref type="figure" target="#fig_3">4B, 4C</ref>).</s><s>Hence, bulk CD3/28activated T cells were derived almost entirely from naive and T CM CD4 + and CD8 1 T cells, with little or no contribution from T EM and T EMRA subsets (Fig. <ref type="figure" target="#fig_3">4B, 4C</ref>).</s><s>Of note, despite their high rate of expansion when cultured in bulk PBMCs, T SCM -derived cells represented ,2% of the bulk cultures on day 14 because of their low starting frequency.</s></p><p><s>By day 14 of culture, T cells with a T EM phenotype (CCR7 2 CD45RO + ) dominated all subset-derived cultures (Supplemental Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>However, a substantial proportion of T cells with a T CM phenotype could be detected within expanded T CM -derived cells (CD4 + 20.4 6 2.9%; CD8 + 13.5 6 2.6%), T naive -derived cells (CD4 + 45.2 6 6.9%; CD8 + 18.5 6 2.4%), and CD8 + T SCM -de-rived cells (19.4 6 2.7%), as well as in bulk PBMC-derived cells (CD4 + 12.4 6 2.8%; CD8 + 15.7 6 3.9%).</s></p><p><s>To evaluate cytokine production in response to CAR stimulation by T cell subset-derived cells expanded within bulk PBMCs, we performed intracellular flow and costained with Abs to NGFR (the marker for the subset) and to the spacer/hinge region of the CD19.</s><s>CAR (Fig. <ref type="figure" target="#fig_4">5A, 5B</ref>) to distinguish subset-and bulk-derived T cells.</s><s>Fig. <ref type="figure" target="#fig_4">5C</ref> and 5D show IFN-g, TNF-a, and IL-2 production from each T cell subset (CD4 + : red bars, CD8 + : blue bars) and from the T cell subset-depleted bulk population (CD4 + : black bars, CD8 + : white bars) in response to a CD19 + mantle cell lymphoma (JEKO) and a CD19 2 Hodgkin lymphoma (HDLM2).</s><s>T naive -derived cells produced relatively low levels of all cytokines compared with bulk-derived T cells and with other subsets, which showed similar capacities to produce cytokines in response to CAR stimulation, even when their frequencies within the cocultures were low (Fig. <ref type="figure" target="#fig_4">5C-E</ref>).</s></p><p><s>We next tested the killing capacity of each subset cultured alone, as well as its respective subset-depleted and subset-reconstituted PBMC cell preparation (Fig. <ref type="figure" target="#fig_5">6A</ref>).</s><s>Fig. <ref type="figure" target="#fig_5">6B</ref> shows the killing capacity Quantification of CCR7 and CD45RO expression 14 d after CD3/28-activation in each T SUBSET -derived population: T CMs (CCR7 + CD45RO + ), T EMs (CCR7 2 CD45RO + ), T EMRAs (CCR7 2 CD45RO 2 ), and T naives (CCR7 + CD45RO 2 ).</s><s>CD4 + (left panel) and CD8 + (right panel) T SUBSET -derived populations.</s><s>(E) CD3/28-expanded T SUBSET -derived populations were restimulated via the CAR using a GD2 + neuroblastoma cell line JF at a stimulator/responder ratio of 10:1 14 d after the initial CD3/28 activation and a non-CAR control stimulation (GD2 2 Hodgkin lymphoma: HDLM-2).</s><s>Shown is background-subtracted (negative control: HDLM-2) IFN-g production to JF by CD4 + (left panel) and CD8 + (right panel) T SUBSET -derived populations, as determined by intracellular staining 6 h after coculture.</s><s>Cells were permeabilized and stained for IFN-g, CD3, CD4, and CD8.</s><s>(F) T SUBSET expansion (measured as fold increase) was analyzed for each cell subset between days 14 and 21 after stimulation with plate-bound GD2 on day 14.</s><s>Mean data from six healthy donors are presented, and error bars represent SEM.</s><s>*p , 0.05, repeated measures one-way ANOVA.</s></p><p><s>by guest on May 17, 2022 http://www.jimmunol.org/</s><s>Downloaded from of each T cell subset cultured alone, T cell subset-depleted bulk population, and T cell subset-reconstituted bulk population in response to a CD19 + mantle cell lymphoma (JEKO) and a CD19 2 Hodgkin lymphoma (HDLM2).</s><s>Intriguingly, killing of CD19 + JEKO cells was significantly reduced in cultures in which T CMs and T EMs were depleted from the bulk PBMC population (Fig. <ref type="figure" target="#fig_5">6B</ref>, top panels).</s><s>In contrast, T cell subset-reconstituted populations showed little variance in their killing (Fig. <ref type="figure" target="#fig_5">6B</ref>, middle panels).</s><s>Comparison of the T cell subsets cultured alone revealed a significantly lower killing capacity of T naive -derived cells (Fig. <ref type="figure" target="#fig_5">6B</ref>, bottom panels).</s></p><p><s>In summary, T naive -derived cells expand preferentially within polyclonally activated PBMCs and express a memory T cell surface marker profile, but they show reduced effector cytokine production and killing compared with memory-derived subsets.</s><s>To evaluate the phenotypic and functional characteristics of each T cell subset cultured in the presence of the whole PBMC preparation compared with T cells cultured alone, we followed the experimental setup presented earlier, which included the transduction of each T cell subset using a retroviral vector encoding a second-generation CD19.CD28z CAR and a truncated NGFR (CD19.CAR-NGFR) and in-parallel transduction of each subsetdepleted PBMC population with the same second-generation CD19.CAR but without NGFR.</s><s>Initially, we followed the fate of individually sorted CAR-transduced T cell subsets after activation, transduction, and culture alone or after reconstitution into the relevant subset-depleted population (Fig. <ref type="figure" target="#fig_6">7A</ref>).</s><s>Each T cell subset differentiated during culture; by day 7 of culture, T cells with T CM and T EM phenotypes (CCR7 + CD45RO + and CCR7 2 CD45RO + , respectively) dominated all subset-derived cultures (Fig. <ref type="figure" target="#fig_6">7</ref>).</s><s>We defined the T CM proportion of each T cell subset as a measure of differentiation.</s><s>When comparing the phenotype of each transduced subset cultured alone or within the transduced bulk PBMC population, we found significantly higher proportions of phenotypically less-differentiated T CMs in separately cultured T CM -and T naive -derived cells (day 14: T CM -derived cells cultured in bulk: CD4 + 13.1 6 2.6%; CD8 + 12.9 6 1.4% versus T CM -derived cells cultured alone: CD4 + 21.7.1 6 9.9%; CD8 + 21.2 6 5.4% and T naive -derived cells cultured in bulk: CD4 + 14.8 6 4.7%; CD8 + 11.2 6 1.1% versus T naive -derived cells cultured alone: CD4 + 39.8 6 7.8%; CD8 + 29.1 6 6.6%) (Fig. <ref type="figure" target="#fig_6">7</ref>).</s><s>A substantial proportion of T cells with a T CM phenotype could also be detected within expanded CD8 + T SCM -derived cells (day 14: T SCM -derived cells cultured in bulk: 15.3 6 1.7% versus T SCM -derived cells cultured alone: 22.6 6 0.9%) (Fig. <ref type="figure" target="#fig_6">7</ref>).</s><s>Of note, T cell cultures derived from less-differentiated T SCM -, T CM -, and T naive -derived cultures had more stable CAR expression in long-term cultures up to day 21, whereas T EM -and T EMRA -derived cultures showed partial loss of their CAR (Supplemental Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>When comparing intracellular cytokine production in response to CAR stimulation (using the CD19 + mantle cell lymphoma [JEKO]) of each transduced subset cultured alone or within the transduced bulk PBMC population, T naive -derived cells produced less IFN-g when cultured within the transduced bulk PBMC population than when cultured alone, whereas all other subsets showed similar IFN-g production, regardless of whether they were cultured in the presence of the whole PBMC preparation or alone (Supplemental Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>T naive -derived cells produced relatively low levels of IFN-g compared with other T cell subsets that produced similar cytokine levels in response to CAR stimulation (Supplemental Fig. <ref type="figure" target="#fig_2">3</ref>).</s></p><p><s>Finally, we compared T cell subset proliferation in response to CD19.CAR stimulation.</s><s>Each transduced subset cultured alone or T cell subset-derived cells expanded within bulk PBMCs were stimulated on day 14 of culture using CD19 + JEKO cells in the presence or absence of exogenous cytokines (IL-7 and IL-15) (Fig. <ref type="figure">8A</ref>), and T cell subset expansion was measured 7 d later.</s></p><p><s>To assess the expansion of each subset cultured in the presence of the whole PBMC preparation, we used Abs to NGFR (T cell subset) and to the spacer/hinge region of CD19.CAR before and after CAR stimulation (Fig. <ref type="figure">8A</ref>).</s><s>In the absence of exogenous cytokines, T EMRA -and T naive -derived cells failed to proliferate, whereas T SCM -, T CM -, and T EM -derived cells expanded to a similar degree, regardless of whether they were cultured alone or within the transduced bulk population (Fig. <ref type="figure">8B</ref>).</s><s>When cultured with cytokines, only T EMRAs did not expand.</s><s>As expected, the expansion of the remaining subsets was much greater than without CAR-NGFR + ) and PBMC T cell subset-derived (CD19.CAR + ) populations within one approach were analyzed using a paired t test.</s><s>*p , 0.05.</s><s>cytokines (Fig. <ref type="figure">8C</ref>) and, notably, T naive -derived cells showed significantly greater expansion when cultured alone than when cultured within the transduced bulk population (65-fold for CD4 + and 36-fold for CD8 + alone compared with 43-fold for CD4 + and 15fold for CD8 + cultured in bulk) (Fig. <ref type="figure">8C</ref>).</s><s>In contrast, all other subsets showed slightly greater expansion when cultured in bulk (Fig. <ref type="figure">8C</ref>).</s></p><p><s>In summary, T naive -derived cells differentiate more when cultured in the presence of memory T cells than when cultured alone, and they show coincidentally reduced effector cytokine production and re-expansion capacity in response to CAR stimulation.</s><s>Overall, T naive -derived cells show reduced effector cytokine production compared with memory-derived subsets, and they lack the ability to respond to stimulation in the absence of cytokines.</s></p><p><s>The yield of T SCM -and T CM -derived T cells is increased by culture in IL-7 with IL-15 compared with culture in IL-2</s></p><p><s>Because the T naive -derived CAR-modified cells that dominated our cultures showed inferior CAR-mediated effector function and may have limited longevity, we aimed to increase the frequencies of T CM -and T SCM -derived cells during expansion of the cultures.</s><s>Therefore, we compared the effects of the two cytokine regimens on relative T cell subset expansion.</s><s>To determine how IL-2 could influence the outgrowth of T CMs and T SCMs within bulk cultures, we reconstituted FACS-purified T CMs and T SCMs , as described earlier (Fig. <ref type="figure" target="#fig_7">9A</ref>), followed by polyclonal activation with CD3 and CD28 Abs in the presence of IL-2 (50 IU/ml) or IL-7 and IL-15 (each at 10 ng/ml) and transduction with a retroviral vector encoding mOrange.</s><s>We reconstituted each subset into its respective subset-depleted population on day 3 and then assessed the fate of T CMs and T SCMs by tracing their path during the course of expansion (Fig. <ref type="figure" target="#fig_7">9B</ref>).</s><s>The medium and cytokines were changed every 3 d during culture and expansion.</s><s>The frequency and absolute numbers of each subset were assessed weekly for up to day 35 after the initial stimulation (Fig. <ref type="figure" target="#fig_7">9C</ref>).</s><s>Although the trend toward higher frequencies of CD4 + or CD8 + T CM -and T SCM -derived cells induced by culture in IL-7 and IL-15 (Fig. <ref type="figure" target="#fig_7">9C</ref>) did not reach significance, we plan to enhance this trend using cytokine modifications and to use our separation approach to validate the changes.</s><s>Owing to the higher overall fold expansion rate of T cells expanded in IL-7 and IL-15, the absolute numbers of T CM -and T SCM -derived cells were significantly higher than in IL-2-grown cultures (Fig. <ref type="figure" target="#fig_7">9D</ref>).</s><s>Furthermore, T cells cultured in IL-2 showed an earlier contraction, as defined by a reduction in cell numbers from day 20, whereas T cells cultured in IL-7 and IL-15 expanded long-term, with no signs of culture contraction up to day 35 (Fig. <ref type="figure" target="#fig_7">9D</ref>).</s><s>These results confirm that IL-7 and IL-15 better supported the expansion of T CMs and T SCMs within bulk cultures <ref type="bibr" target="#b21">(22,</ref><ref type="bibr" target="#b39">39)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The central purpose of our study was to understand the contribution of naive and effector/memory T cell subsets to the bulk in vitrostimulated CAR-stimulated T cell products that are eventually infused into patients in our clinical trials.</s><s>To this end, we developed an approach to assess the fate of each T cell subset by tracing its path during the course of expansion after transduction with a GD2.CAR or a CD19.CAR and cultured alone or after reconstitution into the relevant subset-depleted PBMCs that had been activated and transduced in parallel (e.g., T SCM into T SCM -depleted PBMCs).</s><s>In our proof-of-concept study, we show that all subsets were similarly susceptible to transduction, and the rate of T cell subset expansion was unchanged by transfer into the subsetdepleted population.</s><s>The greatest rate of expansion was observed in T SCM -derived T cells, but because T SCMs represented ,1% (0.9 6 0.2%) of the starting population, their descendants made up ,2% of the final product on day 14.</s><s>Naive-derived T cells showed the second greatest rate of expansion, and this population dominated the cultures by day 14, accounting for up to 89% of CD19.CAR-modified T cells.</s><s>T CMs showed the third greatest rate of proliferation and accounted for up to 44% of the final population.</s><s>T EM -and T EMRA -derived populations proliferated relatively weakly and were poorly represented in the final population (,5 and ,3%, respectively).</s><s>Despite the greatest proliferative response to TCR stimulation, the dominant naivederived T cell majority showed relatively poor cytokine production, killing, and poor proliferative responses to CAR stimulation.</s><s>Further, T naive -derived cells differentiated to a greater extent when cultured in the presence of memory T cells compared with when cultured alone and showed reduced re-expansion capacity in response to CAR stimulation.</s><s>IL-7 and IL-15 induced greater total fold expansion of CD3/28-activated T cells and produced higher frequencies of T CM -and T SCM -derived cells than did IL-2.</s></p><p><s>Successful CAR-modified T cell therapy depends on multiple cell-and patient-dependent factors.</s><s>Among these, the T cell subset origin of the final T cell product infused may be critical to the final outcome by contributing to postinfusion T cell expansion, effector function, and long-term persistence <ref type="bibr" target="#b26">(26,</ref><ref type="bibr" target="#b34">34,</ref><ref type="bibr" target="#b37">37)</ref>.</s><s>However, although the effector memory phenotype of the final CAR-modified T cell product infused is often described, the T cell subset of origin is rarely investigated, so that functional dissection of the infusion product (T EFF products) remains a prerequisite to better understand and correlate therapy outcome with T cell product input.</s><s>Although individual subsets have been expanded in isolation, neither their expansion and function after reconstitution into the bulk population nor the subset contribution to the final T cell product have been reported.</s><s>Of note, we analyzed the T cell subset contribution only of PBMCs activated on CD3 and CD28-coated plates in the presence of IL-7 and IL-15 or IL-2, which are the methods that we have used to expand CARmodified T cells in our clinical trials.</s><s>Many other methods are used by other groups, including CD3/28-coated beads, soluble CD3 and CD28 or PHA, and these may produce different results.</s><s>Regardless, our strategy presents a means to evaluate the effects on T cell subsets resulting from any changes in culture conditions.</s></p><p><s>There is intense discussion about the optimal phenotypic T cell profile and optimal T cell subset for immunotherapeutic use with regard to longevity, engraftment, and antitumor effector function <ref type="bibr" target="#b21">(22,</ref><ref type="bibr" target="#b26">26,</ref><ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b34">(34)</ref><ref type="bibr" target="#b35">(35)</ref><ref type="bibr" target="#b36">(36)</ref><ref type="bibr" target="#b37">(37)</ref>.</s><s>Berger et al. <ref type="bibr" target="#b30">(30)</ref> showed that CMVspecific T EFF clones derived from T CMs exhibited superior engraftment capacities compared with clones derived from T EMs , and they were long-lived and established persistent memory T cells in a primate model in which TCR stimulation was provided by endogenous CMV.</s><s>Other groups have suggested that the T naive population is important, because this subset may contain precursors for tumor-specific Ags that could contribute to tumor elimination <ref type="bibr" target="#b47">(47)</ref>.</s><s>The question of whether naive-derived T cells displaying memory T cell phenotypic characteristics have the capacity for long-term survival in vivo, particularly if they do not encounter their cognate Ag, remains an important subject for investigation.</s><s>Naive to memory T cell conversion is a very complex process that requires multiple encounters with Ag, and it occurs in secondary lymphoid organs that provide an environment for such conversion <ref type="bibr" target="#b48">(48)</ref><ref type="bibr" target="#b49">(49)</ref><ref type="bibr" target="#b50">(50)</ref><ref type="bibr" target="#b51">(51)</ref>.</s><s>Several studies reported effective in vitro T cell priming for multiple viral and tumor Ags; however, their clinical efficacy remains to be demonstrated <ref type="bibr" target="#b51">(51)</ref><ref type="bibr" target="#b52">(52)</ref><ref type="bibr" target="#b53">(53)</ref><ref type="bibr" target="#b54">(54)</ref><ref type="bibr" target="#b55">(55)</ref><ref type="bibr" target="#b56">(56)</ref><ref type="bibr" target="#b57">(57)</ref><ref type="bibr" target="#b58">(58)</ref><ref type="bibr" target="#b59">(59)</ref><ref type="bibr" target="#b60">(60)</ref>.</s><s>In our studies, naive-derived T cells developed effector functions in vitro, but these were less potent than memory-derived T cells.</s><s>Whether such naive-derived T cells with a memory phenotype have long-term memory potential in vivo and whether in vivo CAR stimulation by tumor cells can induce true memory conversion remain to be demonstrated.</s><s>Recently, Sommermeyer et al. <ref type="bibr" target="#b62">(61)</ref> showed that when modified with a CD19.CAR, a combination of CD4 + naive-and CD8 + T CMderived T cells showed the most potent antitumor function in vitro and in preclinical models and in combination had synergistic antitumor effects in an EBV + lymphoma xenograft model (Raji).</s><s>This combination is currently under clinical evaluation.</s><s>A possible advantage of the T CM population is that it contains T cells specific for endogenous viruses that may provide antigenic stimulation after infusion.</s></p><p><s>Gattinoni and colleagues (29) described the existence of stem cell-like T cells (T SCM ) within the phenotypically naive (CD45RA + CCR7 + ) T cell population.</s><s>The expression of CD95 distinguished T SCMs (CD45RA + CCR7 + CD95 + ) from T naives (CD45RA + CCR7 + CD95 2 ) and, in a murine xenograft model, only T SCMs were able to serially transfer graft-versus-host disease <ref type="bibr" target="#b39">(39)</ref>.</s><s>The distinct functional and unique homeostatic properties of T SCMs have also been demonstrated in a nonhuman primate model during the course of SIV infection.</s><s>In that report, T SCMs were described as the least-differentiated memory subset, functionally distinct from conventional memory cells, and they served as precursors of T CMs <ref type="bibr" target="#b38">(38)</ref>.</s><s>In a human study, Xu et al. <ref type="bibr" target="#b36">(36)</ref> suggested that the frequency of T SCM -like cells within the infused T cell product correlated with in vivo expansion following adoptive transfer, whereas Biasco et al. <ref type="bibr" target="#b63">(62)</ref> showed that T SCMs produced the greatest contribution to FIGURE 8. Proliferation of CD19.CAR-modified T cell subset (T SUBSET ) cells cultured alone or expanded within bulk PBMCs in response to CAR stimulation.</s><s>CAR-modified T SUBSET cells were cultured alone or reconstituted into CD19.CAR-modified subset-depleted PBMCs as in Fig. <ref type="figure" target="#fig_2">3</ref>. (A) Each CD3/28-expanded transduced T SUBSET -derived population, cultured alone or within bulk PBMCs, was stimulated via the CAR using vital CD19 + JEKO cells in the presence or absence of exogenous cytokines (IL-7 and IL-15) at a 10:1 stimulator/ratio 14 d after the initial CD3/28 activation.</s><s>The frequency of each subset was measured by costaining with Abs to NGFR and to the spacer/hinge region of the CD19.CAR at assay initiation and after 7 d of consecutive expansion.</s><s>T SUBSET expansion (measured as fold increase) was analyzed for each cell subset between days 14 and 21 after stimulation with CD19 + JEKO cells on day 14 in the absence (B) or presence (C) of exogenous cytokines (IL-7 and IL-15).</s><s>Mean data from three healthy donors are presented, and error bars represent SEM.</s><s>Data from T SUBSET -derived populations (CD19.CAR-NGFR + cultured alone versus cultured within PBMC preparations) were analyzed using a paired t test.</s><s>*p , 0.05.</s><s>long-term reconstitution in gene therapy studies using T cells.</s><s>Hence, T SCMs may have even greater potential for expansion and long-term persistence than T CMs <ref type="bibr" target="#b39">(39)</ref>, but the relative benefits of T CM -and T SCM -derived CAR-modified T cells in clinical trials have not been reported.</s><s>Our data suggest that standard strategies for CAR-modified T cell manufacturing may preferentially expand T naives , with some contribution from T CMs but little contribution from T SCMs , despite the fact that they expand exponentially in vitro when cultured alone or within PBMCs.</s><s>Further studies are required to evaluate the long-term fate of T CM -and T SCM -derived cells, both in culture and in patients.</s></p><p><s>The ultimate T cell subset composition will likely also be affected by the CAR structure and endodomains, but our system provides a way to test these effects on the final infusion product.</s><s>We show that culture conditions profoundly affect the subset composition of expanded T cells.</s><s>IL-2 expansion produced lower total fold expansion than did IL-7 and IL-15 and, thus, decreased the numbers of T SCMs and T CMs in the final product.</s><s>Although not significant, IL-7 and IL-15 also produced higher frequencies of T CM -and T SCM -derived cells than did IL-2.</s><s>Further efforts to improve the relative frequency of T CM /T SCM -derived cells over naive-derived T cells could be validated using our strategy.</s><s>Other culture manipulations, including culture vessels, media formulation, and type of initial stimulus, will likely also influence the degree to which each subset contributes to the final population.</s><s>Indeed, in our prior study, we found that T SCM -derived CMVspecific T cells did not expand within the bulk population if they were stimulated with CMV peptides rather than with CD3 and CD28 Abs <ref type="bibr" target="#b21">(22)</ref>.</s><s>A more direct way to obtain the desired T cell subset is to separate it from the starting population prior to culture, but this increases the expense and complexity of manufacture <ref type="bibr" target="#b62">(61)</ref>.</s><s>It would be instructive to know whether the manufacturing strategies used in various clinical trials promote the outgrowth of T CMs and T SCMs , and it would useful to develop cell culture strategies that enhance their expansion within bulk cultures, without the requirement for separation strategies.</s><s>We provide a strategy to evaluate the subsets of origin of T cells grown under any conditions using PBMCs from patients or healthy donors.</s><s>Our study supports the importance of IL-7 and IL-15 for the expansion of T CM -and T SCM -derived T EFFs , at least using our manufacturing strategy <ref type="bibr" target="#b36">(36)</ref>.</s></p><p><s>Although the different T cell subsets were not differentially transduced by retroviral vectors, their dissimilar rates of proliferation led to changes in their relative frequencies in the final population, which was dominated by naive-derived T cells (76 6 19% of CD3 + T cells).</s><s>T CM -derived populations maintained their frequencies (30 6 12% of CD3 + T cells), and T SCM -derived populations were maintained or slightly increased (mean of 1.5 6 0.3% of CD3 + T cells), whereas T EM and T EMRA frequencies were reduced (mean of 4.7 6 1.6% and 2.8 6 1.3% of CD3 + T cells, respectively).</s><s>Although the majority of each subpopulation differentiated into cells with a T EM -like phenotype, their functionalities differed with respect to cytokine production and proliferation in response to CAR stimulation.</s><s>T naive -and T EMRAderived cells produced lower levels of cytokines and proliferated poorly in response to CAR stimulation compared with T CM -and T SCM -derived cells.</s><s>This may be of little importance for T EMRAs , because they make up only a minor fraction of the final product; however, a high frequency of poorly functional T naive -derived cells may be less effective after infusion.</s><s>Our results confirm reports suggesting that naive-derived T cells possess poor effector functions <ref type="bibr" target="#b37">(37)</ref>.</s><s>However, we cannot exclude the possibility that naivederived T cells will acquire improved function after multiple stimulations in vivo via CAR, although they responded relatively poorly to a single CAR stimulation in vitro.</s><s>Our data confirm the recent report by Klebanoff et al. <ref type="bibr" target="#b27">(27)</ref> showing enhanced phenotypic and functional differentiation of naivederived T cells that have been cultured in the presence of Ag-experienced memory T cells.</s><s>Naive-derived T cells cultured in bulk PBMC preparations show reduced re-expansion capacity in response to CAR stimulation and, hence, may lack antitumor potential when transferred in vivo.</s><s>Nevertheless, when we cultured naive-derived T cells separately, re-expansion to CAR stimulation was reduced compared with T SCM -, T CM -, and T EM -derived cultures.</s><s>Hence, if T naives are to be used for adoptive immunotherapy, we would propose culture in isolation to avoid the negative effects of culture with Ag-experienced memory T cells.</s><s>Further in vitro and in vivo studies over longer time periods are required to determine the long-term consequences of infusing a preponderance of T naive -derived cells; however, without some form of differential gene marking, this may be difficult.</s></p><p><s>Our strategy could also be used in cases in which short-lived effectors are desirable for safety reasons (e.g., to test a novel T cell manipulation).</s><s>Regardless, our strategy can be a powerful tool to evaluate the effects of manufacturing changes on the subset contribution to in vitro-expanded T cells.</s><s>Certainly, a one-sizefits-all strategy for the generation of CAR-modified T EFFs may not be expected because of tumor cell biology and patient characteristics, but a better understanding of the characteristics of the generated CAR-modified T cell products will help to identify the subsets with most clinical efficacy.</s><s>To this end, our strategy provides a powerful tool to elucidate the characteristics of CARmodified T cells polyclonally expanded from PBMCs on CD3 and CD28 Ab-coated plates and to reveal the functional properties of each expanded T cell subset.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc><div><p><s>FIGURE 1. Strategy for T cell subset sorting, activation, and transduction.</s><s>(A) Strategy for sorting T cell subsets from PBMCs according to their expression of CD3+, CD45RA + , CCR7 + , and CD95 + .</s><s>Prior to FACS, CD3 + T cells were enriched from PBMCs by untouched MACS separation.</s><s>They were then sorted into the following subsets: T CMs (CCR7 + CD45RA 2 ), T EMs (CCR7 2 CD45RA 2 ), T EMRAs (CCR7 2 CD45RA + ), T SCMs (CD45RA + CCR7 + → CD95 + ), and T naives (CD45RA + CCR7 + → CD95 2 ).</s><s>(B) FACS-purified T cell populations were isolated to .98% purity.(C)</s><s>Strategy for polyclonal activation and retroviral transduction of T PBMCs [T (TPBMC) ], T CM -derived cells [T (TCM) ], T EM -derived cells [T (TEM) ], T EMRA -derived cells [T (TEMRA) ], T SCMderived cells [T (TSCM) ], and T naive -derived cells [T (Tnaive) ].</s><s>FACS-purified T cell subsets were activated with CD3 and CD28 Abs, cultured in the presence of IL-7 and IL-15 (10 ng/ml each), and transduced on day 2 with a second-generation GD2.CAR (14g2a.CD28-z CAR).</s><s>Shown are examples of GD2.CAR transduction efficacies in separately cultured PBMC-, T CM -, T EM -, T EMRA -, T SCM -, and T naive -derived populations on day 7 postactivation.</s><s>Transduction efficacies were assessed by fluorescence staining for GD2.CAR expression on the T cell surface using the 1A7 Ab targeting 14g2a.</s></p></div></figDesc><graphic coords="5,62.33,61.89,477.86,360.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc><div><p><s>FIGURE 2. Fold expansion and phenotype of separately cultured GD2.CAR-modified T cell subsets (T SUBSETs ) in response to GD2 stimulation.</s><s>(A) FACS-purified T SUBSETs were cultured according to Fig.1.</s><s>GD2 transduction efficacies from six donors.</s><s>CD4 + T SUBSET -derived [T (TSUBSET) ] (left panel) and CD8 + T SUBSET -derived [T (TSUBSET) ] (right panel) populations on day 14 after CD3/28 activation.</s><s>(B) CD4 + /CD8 + proportion within GD2.CAR + T SUBSETS .</s><s>(C) T SUBSET expansion in response to CD3/28 stimulation (measured as fold increase) analyzed for each T SUBSET on days 7 and 14. (D) Quantification of CCR7 and CD45RO expression 14 d after CD3/28-activation in each T SUBSET -derived population: T CMs (CCR7 + CD45RO + ), T EMs (CCR7 2 CD45RO + ), T EMRAs (CCR7 2 CD45RO 2 ), and T naives (CCR7 + CD45RO 2 ).</s><s>CD4 + (left panel) and CD8 + (right panel) T SUBSET -derived populations.</s><s>(E) CD3/28-expanded T SUBSET -derived populations were restimulated via the CAR using a GD2 + neuroblastoma cell line JF at a stimulator/responder ratio of 10:1 14 d after the initial CD3/28 activation and a non-CAR control stimulation (GD2 2 Hodgkin lymphoma: HDLM-2).</s><s>Shown is background-subtracted (negative control: HDLM-2) IFN-g production to JF by CD4 + (left panel) and CD8 + (right panel) T SUBSET -derived populations, as determined by intracellular staining 6 h after coculture.</s><s>Cells were permeabilized and stained for IFN-g, CD3, CD4, and CD8.</s><s>(F) T SUBSET expansion (measured as fold increase) was analyzed for each cell subset between days 14 and 21 after stimulation with plate-bound GD2 on day 14.</s><s>Mean data from six healthy donors are presented, and error bars represent SEM.</s><s>*p , 0.05, repeated measures one-way ANOVA.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 3 .</head><label>3</label><figDesc><div><p><s>FIGURE 3. Experimental design to assess the fate of T cell subsets (T SUBSETs ) polyclonally expanded within PBMCs.</s><s>(A) Strategy for FACS purification of T cell populations: T CMs , T EMs , T EMRAs , T naives , and T SCM were depleted from PBMCs using FACS [(B): T SUBSETS ; (C): T CM depleted from PBMC (PBMC-T CM ), T EM depleted from PBMC (PBMC-T EM ), T EMRA depleted from PBMC (PBMC-T EMRA ), T naive depleted from PBMC (PBMC-T naive ), T SCM depleted from PBMC (PBMC-T SCM )].</s><s>After isolation, each T SUBSET and each single subset-depleted PBMC population were activated with CD3 and CD28 Abs in the presence of IL-7 and IL-15 and then transduced on day 2 with a CD19.CAR construct encoding a marker gene (NGFR); T SUBSET -depleted cells were transduced with CD19.CAR alone (CD19.CD28z CAR).</s><s>Each activated and transduced T SUBSET was reconstituted into the appropriate activated and transduced T SUBSET -depleted PBMCs at their initial frequencies 1 d after transduction to allow tracking of the subset within the bulk population after reconstitution (details in Materials and Methods).</s><s>(D) Representative FACS plots are shown for the flow cytometric detection of each reconstituted CD19.</s><s>CAR-NGFR + T SUBSET -derived [T (TSUBSET) ] population [CD4 + T (TSUBSET) indicated by red dots; CD8 + T (TSUBSET) indicated by blue dots] and the CD19.</s><s>CAR + PBMC-T SUBSET (P-T SUBSET, gray dots) by the assessment of the CD19.CAR and the CD19.CAR-NGFR + , respectively.</s><s>(E) CD19.CAR-NGFR transduction efficacies for CD4 + and CD8 + T CM , T EM , T EMRA , T SCM, and T naive -derived [T (TSUBSET) ] populations (upper panel) and CD19.CAR transduction efficacies for the CD4 + and CD8 + PBMC-T SUBSET (P-T SUBSET ) (lower panel).</s></p></div></figDesc><graphic coords="7,83.69,76.29,440.42,397.82" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIGURE 4 .</head><label>4</label><figDesc><div><p><s>FIGURE 4. Fate of T cell subsets (T SUBSETS ) polyclonally expanded within PBMCs: naive-derived T cells expand preferentially within polyclonally activated PBMCs.</s><s>CAR-modified T SUBSETs were reconstituted into CD19.CAR-modified subset-depleted PBMCs as in Fig. 3. (A) Fold expansion of CD19.</s><s>CAR-NGFR + T SUBSET -derived (T SUBSET ) population cultured alone or after reconstitution into the PBMC-T SUBSET : CD4 + (top panel), CD8 + (middle panel), and whole CD3 + (bottom panel).</s><s>(B) Analysis on day 14 after initial polyclonal activation of each T SUBSET (CD19.CAR-NGFR + ) within PBMC-T SUBSET -expanded T cells (CD19.CAR + ) showing higher frequencies of CD4 + (top panel), CD8 + (blue, middle panel), and whole CD3 + (bottom panel) T (Tnaive) and T (TCM) cells compared with other T (SUBSETs) .</s><s>(C) Frequency of each T SUBSET within CD3 + PBMCs (ex vivo) and frequency at day 14 of CD4 + (upper panel) and CD8 + (lower panel) CD19.CAR-NGFR + T (SUBSETs) within PBMC-T SUBSET -expanded T cells.</s><s>Mean data from six healthy donors are presented, and error bars represent SEM.</s><s>*p , 0.05, repeated-measures one-way ANOVA.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>FIGURE 5 .</head><label>5</label><figDesc><div><p><s>FIGURE 5. Cytokine production by reconstituted T cell subsets in response to CAR stimulation.</s><s>CAR-modified T cell subsets were reconstituted into CD19.CAR-modified subset-depleted PBMCs as in Fig.3.</s><s>On day 14, cultures were stimulated with CD19 2 (HDLM-2) or CD19 + (JEKO) lymphoma cells for 6 h at 10:1 stimulator/ responder ratio.</s><s>Cytokine production was measured by intracellular cytokine staining.(A)</s><s>Representative FACS plots showing IFN-g and TNF-a production by T naive -derived cells in response to HDLM-2 (upper plots) or JEKO (lower plots) cells.</s><s>(B) T cell subsets could be distinguished from the depleted fraction by their expression of NGFR.</s><s>(C-E) Fractions of all subsets producing IFN-g, TNF-a, and IL-2 are shown for CD4 + and CD8 + T cells.</s><s>Cytokine production by transduced and nontransduced PBMCs is also shown.</s><s>Black bars represent PBMC T cell subset-derived CD4 + T cells, red bars represent T cell subset-derived CD4 + T cells, white bars represent PBMC T cell subset-derived CD8 + T cells, and blue bars represent T cell subset-derived CD8 + T cells.</s><s>Mean data from three healthy donors are presented, and error bars represent SEM.</s><s>Data from T cell subset-derived (CD19.CAR-NGFR + ) and PBMC T cell subset-derived (CD19.CAR + ) populations within one approach were analyzed using a paired t test.</s><s>*p , 0.05.</s></p></div></figDesc><graphic coords="9,219.53,96.33,261.50,224.18" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>FIGURE 6 .</head><label>6</label><figDesc><div><p><s>FIGURE 6. Cytotoxic killing capacity of each T cell subsets (T SUBSET )derived population cultured alone and its respective T SUBSET -depleted and T SUBSET -reconstituted PBMC cell preparation.</s><s>Assessment of cytotoxic activity by flow cytometric VITAL assay.</s><s>CAR-modified T cell subsets were cultured alone or reconstituted into CD19.CAR-modified subset-depleted PBMCs, as in Fig. 3. (A) CFSE + CD19 + JEKO cell lines (serving as stimulator APCs for second-generation CD19.CAR T cells) were used as targets, whereas dimethyldodecylamine oxide-succinimidyl ester + CD19 2 HDLM-2 cells lacking CD19 were used as control targets.</s><s>Cells were cocultured for 16 h at T cell/target cell ratios of 1:1 and 10:1.</s><s>Samples without T cells, containing only APCs (CD19 + JEKO cell lines or CD19 2 HDLM-2) were used as internal control.</s><s>The mean percentage of survival of CD19 + JEKO-incubated targets was calculated relative to CD19 2 HDLM-2 controls.</s><s>(B) Killing capacity of each T SUBSET -depleted bulk population (top right panel), T SUBSET -reconstituted bulk population (middle right panel), and T SUBSET cultured alone (bottom right panel).</s><s>Mean data from three healthy donors are presented, and error bars represent SEM.</s><s>*p , 0.05, paired t test.</s></p></div></figDesc><graphic coords="10,56.45,70.65,217.94,391.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>FIGURE 7 .</head><label>7</label><figDesc><div><p><s>FIGURE 7. T cells with T CM and T EM phenotypes dominate all T cell subset-derived populations during culture.</s><s>CAR-modified T cell subsets were cultured alone or reconstituted into CD19.CAR-modified subset-depleted PBMCs, as in Fig. 3. (A) Representative FACS plots illustrating flow cytometric detection of CCR7 and CD45RO expression on days 7, 14, and 21 after initial activation of T cell subset-derived (T TSUBSET ) populations (cultured alone) and of T TSUBSET populations within the relevant PBMC T cell subset preparation (cultured within PBMC).</s><s>(B) Results for T CM phenotype (CCR7 + CD45RO + ) at the indicated time points (days 7, 14, and 21) for all subsets of CD4 + CAR + and CD8 + CAR + T cells.</s><s>Mean data from three healthy donors are presented, and error bars represent SEM.</s><s>Data from T cell subset-derived populations (CD4 + CD19.CAR-NGFR + cultured alone [black bars], CD8 + CD19.</s><s>CAR-NGFR + cultured alone [white bars] versus CD4 + CD19.CAR + cultured within PBMC preparations [red bars] and CD8 + CD19.CAR + cultured within PBMC preparations [blue bars]) were analyzed using a paired t test.</s><s>*p , 0.05.</s></p></div></figDesc><graphic coords="11,53.57,108.45,257.90,154.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>FIGURE 9 .</head><label>9</label><figDesc><div><p><s>FIGURE 9. A combination of IL-7 and IL-15 increases the yield of T SCM -derived [T (TSCM) ] and T CM -derived [T (TCM) ] T cells compared with IL-2.</s><s>T CMs and T SCMs were FACS depleted from PBMCs, activated with CD3 and CD28 Abs in the presence of IL-2 (50 IU/ml) or IL-7 and IL-15 (each at 10 ng/ml), and transduced on day 2 with a retroviral vector encoding mOrange.</s><s>mOrange + T CMs and T SCMs were reconstituted on day 3 to the respective T cell subsetdepleted PBMC.</s><s>The medium and cytokines were changed every 3 d during culture or when passaging the T cells for splitting during expansion.</s><s>(A) Frequency of T SCMs and T CMs in PBMCs.</s><s>(B) Representative plots showing the frequency of mOrange + T CM -derived and T SCM -derived populations in reconstituted cultures on day 11.</s><s>Cells were stained for CD3, CD4, and CD8.</s><s>(C) Frequencies of reconstituted CD4 + T CMs (top panel), CD8 + T CMs (middle panel), and CD8 + T SCMs (bottom panel) during expansion from days 2 to 35 of culture in IL-2 or IL-7 and IL-15 [T CM -derived: T (TCM) ; T SCM -derived: T (TSCM) ]. (D) Expansion within the bulk population of reconstituted CD4 + T CMs (top panel), CD8 + T CMs (middle panel), and CD8 + T SCMs (bottom panel) measured as fold increase of mOrange + T cells over 35 d of culture in IL-2 or IL-7/15.</s><s>Mean data from four healthy donors are presented.</s><s>*p , 0.05, repeated-measures two-way ANOVA.</s></p></div></figDesc><graphic coords="13,151.01,95.37,332.42,417.74" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">by guest on May 17, 2022 http://www.jimmunol.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">The Journal of Immunology</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We thank Dr. Jason Millward (Institute of Medical Immunology, Charite Úniversity Medicine Berlin and Experimental and Clinical Research Center, a joint cooperation between the Charite ´Medical Faculty and the Max-Delbr€ uck Center for Molecular Medicine) for statistical advice.</s><s>This project was supported in part by the Cytometry and Cell Sorting Core at Baylor College of Medicine and the expert assistance of Joel M. Sederstrom and team.</s><s>We thank Dr. Juan F. Vera (Center for Gene Therapy, Baylor College of Medicine) for the generous provision of the SFG.IRES.</s><s>mOrange construct, as well as Tatiana Goltsova and Dr. Amos Gaikwad (Texas Children's Hospital Flow Cytometry Core Laboratory) for technical flow cytometry assistance.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosures</head><p><s>C.M.R. is on the scientific advisory board of Cell Medica.</s><s>The other authors have no financial conflicts of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Adoptive cell transfer: a clinical path to effective cancer immunotherapy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Restifo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dudley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="299" to="308" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bagg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="725" to="733" />
			<date type="published" when="2011-06">June. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bagg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="95" to="73" />
			<date type="published" when="2011-06">June. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Chimeric antigen receptor-modified T cells for acute lymphoid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Aplenc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Rheingold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Teachey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hauck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Wright</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1509" to="1518" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients</title>
		<author>
			<persName><forename type="first">B</forename><surname>Savoldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Mims</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Carrum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Kamble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bollard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Gee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Mei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="1822" to="1826" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kuwana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Asakura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Utsunomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakanishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Arata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Itoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nagase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kurosawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="960" to="968" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Endowing T cells with antibody specificity using chimeric T cell receptors</title>
		<author>
			<persName><forename type="first">G</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Eshhar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="3370" to="3378" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Design and development of therapies using chimeric antigen receptor-expressing T cells</title>
		<author>
			<persName><forename type="first">G</forename><surname>Dotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gottschalk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Savoldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Brenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol. Rev</title>
		<imprint>
			<biblScope unit="volume">257</biblScope>
			<biblScope unit="page" from="107" to="126" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Milone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Fish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Carpenito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Binder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Teachey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Samanta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lakhal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gloss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Danet-Desnoyers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Ther</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1453" to="1464" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Matsushita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Plotkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Riviere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sadelain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Ther</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="413" to="420" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Till</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Greisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Raubitschek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Forman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="2261" to="2271" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Popplewell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Digiusto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Ostberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Forman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol. Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1245" to="1256" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Brentjens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rivie `re</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Davila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stefanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bartido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Borquez-Ojeda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="4817" to="4828" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Kochenderfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Janik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dudley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stetler-Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Maric</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raffeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Lanier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="4099" to="4102" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Kochenderfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Dudley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kassim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Telford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Hakim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Halverson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Hardy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="4129" to="4139" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Till</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Gopal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Maloney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Lindgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Budde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="3940" to="3950" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Brentjens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Davila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Riviere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Cowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bartido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stefanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Olszewska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="177" to="215" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Ritchie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Neeson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peinert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tainton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ho ¨nemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Ther</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2122" to="2129" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Micklethwaite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Savoldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Diouf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="2965" to="2973" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Antibody-modified T cells: CARs take the front seat for hematologic malignancies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Maus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="2625" to="2635" />
			<date type="published" when="2014-06">June. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hudecek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Lupo-Stanghellini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Kosasih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sommermeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="3153" to="3164" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schmueck-Henneresse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sharaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Weist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Landwehr-Kenzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuehrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jurisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Babel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rooney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-D</forename><surname>Volk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="5559" to="5567" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Savoldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Goss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Hammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Gee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Quiros-Tejeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schubert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="2942" to="2949" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">T-cell therapy in the treatment of post-transplant lymphoproliferative disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bollard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rooney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Heslop</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="510" to="519" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Brestrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zwinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schm€ Uck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ro ¨hmhild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Hammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kurtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Uharek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Knosalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lehmkuhl</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy</title>
	</analytic>
	<monogr>
		<title level="j">Am. J. Transplant</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1679" to="1684" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Terakura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Gardner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Turtle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="72" to="82" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Klebanoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Leonardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ouyang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ramaswamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roychoudhuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Eil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="318" to="334" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Two subsets of memory T lymphocytes with distinct homing potentials and effector functions</title>
		<author>
			<persName><forename type="first">F</forename><surname>Sallusto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lenig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fo ¨rster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lanzavecchia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">401</biblScope>
			<biblScope unit="page" from="708" to="712" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">A human memory T cell subset with stem cell-like properties</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gattinoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lugli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Pos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Paulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Quigley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gostick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Carpenito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1290" to="1297" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates</title>
		<author>
			<persName><forename type="first">C</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Lansdorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="294" to="305" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Preferential expansion of human virus-specific multifunctional central memory T cells by partial targeting of the IL-2 receptor signaling pathway: the key role of CD4+ T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schmueck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hammoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brestrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuehrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-H</forename><surname>Luu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Babel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-D</forename><surname>Volk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reinke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="5189" to="5198" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Carrasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Godelaine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Pel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Boon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Bruggen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="2897" to="2905" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="1888" to="1898" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Naranjo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bautista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W.-C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Aguilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Ostberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunother</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="689" to="701" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sommermeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Balakrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Salter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hudecek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Maloney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Turtle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer J</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="141" to="144" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Durett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dakhova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Creighton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Gee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Heslop</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="3750" to="3759" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Hinrichs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">A</forename><surname>Borman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gattinoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Burns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Klebanoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Kerkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="808" to="814" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Superior T memory stem cell persistence supports long-lived T cell memory</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lugli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Dominguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gattinoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Chattopadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Bolton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Klatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brenchley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vaccari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gostick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="594" to="599" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors</title>
		<author>
			<persName><forename type="first">N</forename><surname>Cieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Camisa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cocchiarella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Forcato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Provasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bondanza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bordignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peccatori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ciceri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="573" to="584" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lugli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gattinoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roberto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mavilio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Restifo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roederer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Protoc</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="33" to="42" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells</title>
		<author>
			<persName><forename type="first">`</forename><surname>Pule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Straathof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Heslop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rooney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Brenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="933" to="941" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Rossig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bollard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Nuchtern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Merchant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Brenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="228" to="236" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Loskog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Giandomenico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rossig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Brenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1819" to="1828" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2</title>
		<author>
			<persName><forename type="first">G</forename><surname>Sen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chakraborty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Foon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Reisfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bhattacharya-Chatterjee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1969" to="1976" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The VITAL assay: a versatile fluorometric technique for assessing CTL-and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Silk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Palmowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Gileadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mccarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Salio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ronchese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cerundolo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol. Methods</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="25" to="40" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">HCMV-specific T-cell therapy: do not forget supply of help</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hammoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmueck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuehrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Akyuez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Schefold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Raftery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Scho ¨nrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kaufmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunother</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="93" to="101" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wo ¨lfl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Merker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Morbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Van Gool</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eyrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Schlegel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol. Immunother</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="173" to="186" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The immunological synapse: a molecular machine controlling T cell activation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Grakoui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Bromley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sumen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Dustin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="221" to="227" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bousso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Robey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="579" to="585" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Dynamic imaging of T cell-dendritic cell interactions in lymph nodes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Stoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Delon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Brotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Germain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="page" from="1873" to="1876" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Mempel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Henrickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">H</forename><surname>Von Andrian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">427</biblScope>
			<biblScope unit="page" from="154" to="159" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Berard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Davoust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Neidhart-Berard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nouri-Shirazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Taquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rimoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Cerottini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Banchereau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Palucka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="1535" to="1544" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Sassano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leistritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Eatrides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Phogat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Koff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Drake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Iii</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol. Methods</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="8" to="19" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Hanley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Melenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nikiforow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Scheinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Blaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Demmler-Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Krance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Leung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="285" to="263" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wolfl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuball</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol. Methods</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="40" to="52" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Antigen-specific activation and cytokinefacilitated expansion of naive, human CD8+ T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wo ¨lfl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Protoc</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="950" to="966" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schlienger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Craighead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="3490" to="3498" />
			<date type="published" when="2000-06">June. 2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Santegoets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Schreurs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Masterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goletz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baumeister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Kueter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Lougheed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Van Den Eertwegh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Scheper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol. Immunother</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1480" to="1490" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Naive CD8(+) T cell derived tumorspecific cytotoxic effectors as a potential remedy for overcoming TGF-b immunosuppression in the tumor microenvironment</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-H</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-S</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-O</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Rep</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">28208</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<monogr>
		<title level="m" type="main">Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tuettenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jonuleit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Uting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Br€ Uck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Knop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Enk</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">+ T cells: implications for an efficient vaccination strategy</title>
	</analytic>
	<monogr>
		<title level="j">Gene Ther</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="243" to="250" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sommermeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hudecek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Kosasih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gogishvili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Maloney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Turtle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="492" to="500" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Biasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Scala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ricci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dionisio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baricordi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Calabria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Giannelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Barzaghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pajno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="273" to="286" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
